NRX Pharmaceuticals: FDA Reclassifies ANDA Amendment, GDUFA Date Nov 10, 2026

What Happened
NRX Pharmaceuticals, Inc. (NRXP) announced in an 8-K filed Sept. 16, 2026 that, per a Sept. 15, 2026 communication from the FDA Office of Generic Drugs Director of Regulatory Operations, an amendment to its Abbreviated New Drug Application (ANDA) that had been classified as a Major Amendment has been reclassified as a Minor Amendment. The FDA’s acknowledgement letter revised the GDUFA goal date to November 10, 2026 and noted the reclassified amendment “will not require a substantial expenditure of FDA resources.” A company press release dated Sept. 15, 2026 is attached as Exhibit 99.1 to the filing.

Key Details

• Filing: Form 8-K filed Sept. 16, 2026 announcing the FDA communication.
• Regulatory change: ANDA amendment reclassified from "Major Amendment" to "Minor Amendment."
• New timeline: FDA set a revised GDUFA goal date of November 10, 2026.
• FDA rationale: The agency stated the reclassified amendment will not require substantial additional FDA resources.

Why It Matters
This update gives investors clearer regulatory timing for NRX’s ANDA review by the FDA. Reclassification from Major to Minor and a specific GDUFA goal date reduce uncertainty about the agency’s near-term review workload for this submission. While not an approval or guarantee of approval, the letter is a factual regulatory milestone that can affect the perceived timeline and regulatory risk for the product under review.